Name: Naisulide 100 mg 10 sachets buy
Price: 26.0 EUR
Availability: InStock

Naisulide 100 mg 10 sachets

Product Details

Nаisulide 100 mg 10 sachets is a powerful medicine designed to relieve pain and inflammation. Each sachet contains 100 mg of naifenic acid, which has a strong analgesic and anti-inflammatory effect. This medicine is usually recommended for the treatment of pain in rheumatism, arthritis, myalgia, neuralgia and other conditions. The convenient packaging of the sachet makes it easy and convenient to use, especially when traveling or outside the home. Nisulide 100 mg 10 sachets is an excellent choice for fast and effective pain and inflammation relief.

Composition:

nimesulide 100 mg

Pharmacotherapeutic group

Nonsteroidal anti-inflammatory drug (NSAID)

Indications for use

Acute pain syndrome: algodismenorrhea, postoperative and post-traumatic pain, arthralgia, myalgia, toothache and headache, tendinitis, bursitis.

Symptomatic treatment of osteoarthritis accompanied by pain syndrome (the drug is intended for symptomatic therapy, reducing pain and inflammation at the time of use, does not affect the progression of the disease; nimesulide should be prescribed only as second-line therapy).

Contraindications to use

Hypersensitivity to nimesulide or to other components of the drug;

a complete or incomplete combination of bronchial asthma, recurrent nasal polyposis, paranasal sinuses and intolerance to acetylsalicylic acid and (NSAIDs) (including in the anamnesis);

hepatotoxic reactions to nimesulide in the anamnesis;

concomitant use with other drugs with potential hepatotoxicity (e.g. other NSAIDs);

chronic inflammatory bowel diseases (Crohn's disease, ulcerative colitis) in the acute phase;

the period after coronary artery bypass grafting;

febrile syndrome in colds and acute respiratory viral infections;

suspicion of acute surgical pathology;

peptic ulcer of the stomach or duodenum in the acute phase;

erosive and ulcerative lesions of the gastrointestinal tract in the acute phase;

erosive and ulcerative lesions of the gastrointestinal tract in the anamnesis;

a history of perforation or gastrointestinal bleeding, including those associated with previous NSAID therapy;

a history of cerebrovascular bleeding, other active bleeding or diseases accompanied by increased bleeding;

severe blood clotting disorders;

severe heart failure;

severe renal insufficiency (creatinine clearance less than 30 ml/min);

progressive kidney disease;

confirmed hyperkalemia;

liver failure, active liver disease;

children under 12 years of age;

pregnancy and breastfeeding;

alcoholism, drug addiction.

Side effects

Data from clinical and epidemiological studies indicate that long-term use of any NSAIDs (especially in high doses) may potentially be accompanied by an increased risk of arterial thrombosis (including manifested by myocardial infarction or ischemic stroke).

Against the background of the use of NSAIDs, edematous syndrome, arterial hypertension, and worsening of the course of heart failure may develop. Very rarely have serious skin reactions been reported, including Stevens–Johnson syndrome and toxic epidermal necrolysis.

Various gastrointestinal disorders are most often observed (especially in predisposed and elderly people): peptic ulcers, perforation of the wall of the gastrointestinal tract, the development of potentially severe gastrointestinal bleeding, nausea, vomiting, bloody vomiting, flatulence, abdominal pain, diarrhea, constipation, melena, stomatitis, ulcerative colitis, manifestations of gastritis are less common.

The following adverse events against the background of taking nimesulide were identified during controlled clinical trials (marked with "*"), as well as marketing observations with the presented frequency, classified according to the recommendations of the World Health Organization: very often (at least 10%); often (1-10%); infrequently (0.1–1%); rarely (0.01–0.1%); very rarely (less than 0.01%, including individual cases).

Disorders of the blood and lymphatic system: rarely - anemia*, eosinophilia*; very rarely - thrombocytopenia, pancytopenia, purpura.

Disorders of the immune system: rarely – hypersensitivity*; very rarely – anaphylaxis.

Metabolic and nutritional disorders: rarely – hyperkalemia.

Disorders of the nervous system: rarely – anxiety, fear*, nervousness*, "nightmarish" dreams*, infrequently – dizziness*.

Visual disturbances: rarely – blurred vision*; very rarely – visual disturbances.

Disorders of the heart and blood vessels: infrequently – arterial hypertension*; rarely – tachycardia*, lability of blood pressure*, "flushes" of blood to the face*.

Disorders of the respiratory system, chest and mediastinal organs: infrequently – dyspnea*; very rarely – bronchospasm.

Gastrointestinal disorders: often – diarrhea*, nausea*, vomiting*; infrequently – constipation*, flatulence*, gastritis*; very rarely – abdominal pain, dyspepsia, stomatitis, melena, gastrointestinal bleeding, ulcer and perforation of the duodenum and/ or stomach.

Disorders of the liver and biliary tract: often – increased activity of "liver" enzymes*; very rarely – hepatitis, including lightning-fast course, jaundice, cholestasis.

Disorders of the skin and subcutaneous tissues: infrequently – itching*, rash*, increased sweating*; rarely – erythema*, dermatitis*; very rarely – urticaria, angioedema, facial edema, erythema multiforme, Stevens – Johnson syndrome, toxic epidermal necrolysis.

Disorders of the kidneys and urinary tract: rarely – dysuria*, hematuria*, urinary retention*; very rarely – renal failure, oliguria, interstitial nephritis.

General disorders and reactions at the injection site: infrequently – edematous syndrome*; rarely – malaise*, asthenia*; very rarely – hypothermia.

Method of administration and dosage

The minimum effective dose should be prescribed with the shortest possible course of treatment. The maximum duration of treatment with nimesulide is 15 days.

Adults: 100 mg of nimesulide 2 times a day after meals.

Elderly people: there is no need to reduce the daily dose.

Children (under 12 years of age): the drug Nisulid® is contraindicated.

Teenagers (from 12 to 18 years old): No dose adjustment is required.

Patients with impaired renal function: dose adjustment in patients with mild to moderate renal impairment (CC 30-60 ml/min) is usually not required. The drug Nisulide® is contraindicated in case of severe renal dysfunction (CC < 30 ml /min).

Patients with impaired liver function: the use of the drug Nisulide is contraindicated.